2-{2-[(E)-2-(3-chloro-phenyl)-vinyl]-pyrimidin-4-yl}-1-methyl-1,5,6,7-tetrahydro-pyrrolo[3,2-c]pyridin-4-one | 1258961-33-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并吡啶类
• 英文名称: 2-{2-[(E)-2-(3-chloro-phenyl)-vinyl]-pyrimidin-4-yl}-1-methyl-1,5,6,7-tetrahydro-pyrrolo[3,2-c]pyridin-4-one
• 英文别名: 2-[2-[(E)-2-(3-chlorophenyl)ethenyl]pyrimidin-4-yl]-1-methyl-6,7-dihydro-5H-pyrrolo[3,2-c]pyridin-4-one
• CAS: 1258961-33-9
• 化学式: C₂₀H₁₇ClN₄O
• 分子量: 364.834
• InChiKey: YZPMQNQNZOHDOP-AATRIKPKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  26
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  59.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  2-{2-[(E)-2-(3-chloro-phenyl)-vinyl]-pyrimidin-4-yl}-1-methyl-4-oxo-1,4,6,7-tetrahydro-pyrrolo[3,2-c]pyridine-5-carboxylic acid tert-butyl ester 在 甲醇 作用下， 以 盐酸1,4-二恶烷 为溶剂， 反应 1.0h， 以yielding 2-{2-[(E)-2-(3-Chloro-phenyl)-vinyl]-pyrimidin-4-yl}-1-methyl-1,5,6,7-tetrahydro-pyrrolo[3,2-c]pyridin-4-one as a yellow solid (0.015 g, 0.041 mmol, 38%)的产率得到2-{2-[(E)-2-(3-chloro-phenyl)-vinyl]-pyrimidin-4-yl}-1-methyl-1,5,6,7-tetrahydro-pyrrolo[3,2-c]pyridin-4-one
  参考文献：
  名称：

  Substituted pyrimidinylpyrrolopyridinone derivatives, process for their preparation and their use as kinase inhibitors

  摘要：

  本发明公开了式（I）中定义的嘧啶基吡咯吡啶酮衍生物及其药学上可接受的盐，以及它们的制备方法和包含它们的制药组合物；该发明的化合物可能在治疗与蛋白激酶活性失调相关的疾病，如癌症中有用。

  公开号：

  US08546413B2

文献信息

• [EN] SUBSTITUTED PYRIMIDINYLPYRROLOPYRIDINONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS<br/>[FR] DÉRIVÉS DE PYRIMIDINYLPYRROLOPYRIDINONE SUBSTITUÉS, PROCÉDÉ POUR LEUR PRÉPARATION ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE KINASE
  申请人：NERVIANO MEDICAL SCIENCES SRL

  公开号：WO2010145998A1

  公开（公告）日：2010-12-23

  Pyrimidinylpyrrolopyridinone derivatives of formula (I) as defined in the specification, and pharmaceutically acceptable salts thereof, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful, in therapy, in the treatment of diseases associated with a disregulated protein kinase activity, like cancer.

  公开了规范中定义的式（I）的嘧啶基吡咯吡啶酮衍生物及其药学上可接受的盐，其制备方法以及包含它们的药物组合物；本发明的化合物可能在治疗中对与蛋白激酶活性失调有关的疾病，如癌症，具有用处。
• SUBSTITUTED PYRIMIDINYLPYRROLOPYRIDINONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS
  申请人：Marchionni Chiara

  公开号：US20120178770A1

  公开（公告）日：2012-07-12

  Pyrimidinylpyrrolopyridinone derivatives of formula (I) as defined in the specification, and pharmaceutically acceptable salts thereof, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful, in therapy, in the treatment of diseases associated with a disregulated protein kinase activity, like cancer.

  本发明公开了式（I）中定义的嘧啶基吡咯吡啶酮衍生物及其药学上可接受的盐，以及制备它们的方法和包含它们的制药组合物；该发明的化合物可能在治疗与蛋白激酶活性失调有关的疾病，如癌症中有用。
• US8546413B2
  申请人：——

  公开号：US8546413B2

  公开（公告）日：2013-10-01
• US8969366B2
  申请人：——

  公开号：US8969366B2

  公开（公告）日：2015-03-03
• Substituted pyrimidinylpyrrolopyridinone derivatives, process for their preparation and their use as kinase inhibitors
  申请人：Marchionni Chiara

  公开号：US08969366B2

  公开（公告）日：2015-03-03

  Pyrimidinylpyrrolopyridinone derivatives of formula (I) as defined in the specification, and pharmaceutically acceptable salts thereof, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful, in therapy, in the treatment of diseases associated with a disregulated protein kinase activity, like cancer.

  本发明揭示了式（I）中定义的嘧啶基吡咯吡啶酮衍生物及其药学上可接受的盐，其制备过程和包含它们的制药组合物；本发明的化合物可能在治疗与蛋白激酶活性失调有关的疾病，如癌症方面有用。